Limits...
Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study.

Kibaru EG, Nduati R, Wamalwa D, Kariuki N - AIDS Res Ther (2015)

Bottom Line: HIV infected children aged 5-144 months were enrolled if they had received antiretroviral drugs for at least 6 months with available and complete laboratory results.There was significant increase in Hb, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and platelets above the baseline measurements (p < 0.0001) and a significant decline in total white blood cell counts >11,000 cell/mm(3) but a none significant decrease in red blood cells (RBC).Hematological abnormalities changed significantly within 6 months of antiretroviral therapy with significant increase in hemoglobin level, MCV, MCH and platelet and decrease in WBC and RBC.

View Article: PubMed Central - PubMed

Affiliation: Department of Paediatrics and Child Health, Egerton University, P.O. Box 536-20115, Egerton, Kenya ; P.O. Box 2275-20100, Nakuru, Kenya.

ABSTRACT

Background: HIV infected children experience a range of hematological complications which show marked improvement within 6 months of initiating anti-retroviral therapy. The Objectives of the study was to describe the changes in hematological indices of HIV-1 infected children following 6 months of treatment with first line antiretroviral drugs (ARVs) regimen.

Methods: A retrospective study was conducted between September and November 2008. During this period medical records of children attending Comprehensive Care Clinic at Kenyatta National hospital were reviewed daily. HIV infected children aged 5-144 months were enrolled if they had received antiretroviral drugs for at least 6 months with available and complete laboratory results.

Results: Medical records of 337 children meeting enrollment criteria were included in the study. The median age was 63 months with equal male to female ratio. Following 6 months of HAART, prevalence of anemia (Hemoglobin (Hb) <10 g/dl) declined significantly from 35.9 to 16.6 % a nearly 50 % reduction in the risk of anemia RR = 0.56 [(95 % CI 0.44, 0.70) p < 0.001]. There was significant increase in Hb, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and platelets above the baseline measurements (p < 0.0001) and a significant decline in total white blood cell counts >11,000 cell/mm(3) but a none significant decrease in red blood cells (RBC). Pre-HAART, World Health Organization (WHO) stage 3 and 4 was associated with a ten-fold increased likelihood of anemia. Chronic malnutrition was associated with anemia but not wasting and immunologic staging of disease.

Conclusion: Hematological abnormalities changed significantly within 6 months of antiretroviral therapy with significant increase in hemoglobin level, MCV, MCH and platelet and decrease in WBC and RBC.

No MeSH data available.


Related in: MedlinePlus

Comparison of platelet levels at baseline and after 6 months of treatment
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4537535&req=5

Fig1: Comparison of platelet levels at baseline and after 6 months of treatment

Mentions: Proportion of children with platelet counts below 150,000/mm3 before and after 6 months of ARV was 20 and 6.5 % respectively, a significant reduction in the risk of thrombocytopenia RR = 0.46 [(95 % CI 0.32, 0.66) p < 0.0001] as shown in Table 3. At baseline the median platelets counts were 255 × 103/mm3 (IQR 159 × 103/mm3–352 × 103/mm3), and which increased to a median of 279 × 103/mm3 (IQR 224 × 103/mm3–349 × 103/mm3) following 6 months of ART as shown in Fig. 1.Fig. 1


Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study.

Kibaru EG, Nduati R, Wamalwa D, Kariuki N - AIDS Res Ther (2015)

Comparison of platelet levels at baseline and after 6 months of treatment
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4537535&req=5

Fig1: Comparison of platelet levels at baseline and after 6 months of treatment
Mentions: Proportion of children with platelet counts below 150,000/mm3 before and after 6 months of ARV was 20 and 6.5 % respectively, a significant reduction in the risk of thrombocytopenia RR = 0.46 [(95 % CI 0.32, 0.66) p < 0.0001] as shown in Table 3. At baseline the median platelets counts were 255 × 103/mm3 (IQR 159 × 103/mm3–352 × 103/mm3), and which increased to a median of 279 × 103/mm3 (IQR 224 × 103/mm3–349 × 103/mm3) following 6 months of ART as shown in Fig. 1.Fig. 1

Bottom Line: HIV infected children aged 5-144 months were enrolled if they had received antiretroviral drugs for at least 6 months with available and complete laboratory results.There was significant increase in Hb, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and platelets above the baseline measurements (p < 0.0001) and a significant decline in total white blood cell counts >11,000 cell/mm(3) but a none significant decrease in red blood cells (RBC).Hematological abnormalities changed significantly within 6 months of antiretroviral therapy with significant increase in hemoglobin level, MCV, MCH and platelet and decrease in WBC and RBC.

View Article: PubMed Central - PubMed

Affiliation: Department of Paediatrics and Child Health, Egerton University, P.O. Box 536-20115, Egerton, Kenya ; P.O. Box 2275-20100, Nakuru, Kenya.

ABSTRACT

Background: HIV infected children experience a range of hematological complications which show marked improvement within 6 months of initiating anti-retroviral therapy. The Objectives of the study was to describe the changes in hematological indices of HIV-1 infected children following 6 months of treatment with first line antiretroviral drugs (ARVs) regimen.

Methods: A retrospective study was conducted between September and November 2008. During this period medical records of children attending Comprehensive Care Clinic at Kenyatta National hospital were reviewed daily. HIV infected children aged 5-144 months were enrolled if they had received antiretroviral drugs for at least 6 months with available and complete laboratory results.

Results: Medical records of 337 children meeting enrollment criteria were included in the study. The median age was 63 months with equal male to female ratio. Following 6 months of HAART, prevalence of anemia (Hemoglobin (Hb) <10 g/dl) declined significantly from 35.9 to 16.6 % a nearly 50 % reduction in the risk of anemia RR = 0.56 [(95 % CI 0.44, 0.70) p < 0.001]. There was significant increase in Hb, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and platelets above the baseline measurements (p < 0.0001) and a significant decline in total white blood cell counts >11,000 cell/mm(3) but a none significant decrease in red blood cells (RBC). Pre-HAART, World Health Organization (WHO) stage 3 and 4 was associated with a ten-fold increased likelihood of anemia. Chronic malnutrition was associated with anemia but not wasting and immunologic staging of disease.

Conclusion: Hematological abnormalities changed significantly within 6 months of antiretroviral therapy with significant increase in hemoglobin level, MCV, MCH and platelet and decrease in WBC and RBC.

No MeSH data available.


Related in: MedlinePlus